Onco Actu du 19 février 2018

	1. Biologie
Scientists reveal protein that all cells rely on to divide at the right time [institute of Cancer Research] Having shown that Cyclin-B1 is necessary for cell division in very early mouse embryos, the researchers now plan to study Cyclin-B1 in human cancer cells and healthy cells.
	4.2 Dép., diag. & prono. - Génome
George Church: 'Genome sequencing is like the internet back in the late 1980s.' [The Guardian] The pioneering geneticist on why he wants us to earn money by sharing our genomic data, his plans to resurrect the woolly mammoth and how narcolepsy helps him generate ideas.
	4.7 Dép., diag. & prono. - Col de l'utérus
A look at cervical cancer prevention and screening [Stanford Medicine] Using cervical cancer as an example, Lowy outlined how a molecular understanding of the initiation and progression of a disease can refine screening and prevention efforts -- potentially making them more efficient and cost-effective.
	5.10 Traitements - Essais
FDAAA TrialsTracker: A live informatics tool to monitor compliance with FDA requirements to report clinical trial results [bioRxiv] Non-publication of clinical trials results is an ongoing issue. The US government recently updated the requirements on results reporting for trials registered at ClinicalTrials.gov. We set out to develop and deliver an online tool which publicly monitors compliance with these reporting requirements, facilitates open public audit, and promotes accountability.
	5.12.4 Immunothérapies - Essais
Pfizer's Bavencio flops third key study, this time in lung cancer. Can crossover really explain it? [FiercePharma] Pfizer and Merck KGaA have already come up short in two other key trials—one testing Bavencio (avelumab) in a range of solid tumors alongside an immuno-oncology candidate dubbed “4-1BB,” and one in third-line gastric cancer.
	5.12.6 Immunothérapies - AMM
US FDA approves Imfinzi for unresectable Stage III non-small cell lung cancer [AstraZeneca] Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo).
AstraZeneca's immunotherapy drug wins key lung cancer approval [Reuters] Imfinzi is the first immunotherapy to be approved in this setting and the company’s shares rose 1 percent in early trade on Monday.
FDA OK makes AstraZeneca the leader in one new segment of the all-important lung cancer market [EndPoints] The approval only 5 months after the data were unveiled underscores the FDA’s desire to push through cancer drugs from top players like this at an unprecedented speed, when the data comes up in their favor.
FDA expands approval of Imfinzi to reduce the risk of non-small cell lung cancer progressing [FDA] The approval of Imfinzi (durvalumab) for the treatment of stage III, unresectable NSCLC was based on a randomized trial of 713 patients whose cancer had not progressed after completing chemotherapy and radiation.
	5.12.7 Immunothérapies - vaccins
Using stem cells to generate an immune attack against cancer [FierceBiotech] The Stanford researchers used cells from each of the 75 mice in the study to create an iPSC vaccine that targeted several tumor “antigens,” which are markers on the surface of cells that immunotherapies target.
Induced pluripotent stem cells could serve as cancer vaccine [Stanford Medicine] If successful, they envision a future in which people could receive a vaccine comprised of their own irradiated iPS cells as a way to prevent the development of cancers months or years later. Alternatively, the iPS cells could potentially be used as a part of the standard of adjuvant care after primary surgery; chemotherapy or radiation therapy, or both; or immunotherapy as a way to treat established cancers.
Stem Cell Vaccine Protects Mice From Cancer [The Scientist] Using a patient’s own cells as a vaccine might be expected to run the risk of inducing autoimmunity, but in the mice at least, says Kooreman, no signs of increased inflammatory signals nor any self-reactive antibodies were detected.
	5.2.2 Pharma - Fusions & Acquisitions
Flatiron’s Next Phase [Flatiron] We have enough doctors and clinicians on our team that we used to joke that if this whole Flatiron thing didn’t work out, we could start a cancer center.
The Deeply Human Core of Roche's $2.1B Tech Acquisition - And Why They Did It [Forbes] Flatiron has created a dataset that seems largely distinct in the industry – a meticulously assembled oncology dataset that pulls information from the electronic health records and organizes it in a fashion that approaches the quality of clinical research, enabling investigators (and regulators) to ask questions of the data that might normally require a dedicated, stand-alone study to resolve.
Why Flatiron’s Big Exit May Not Be the Boon for Digital Health That Some Expect [Health Advances Blog] Flatiron’s dataset is the most obvious reason for Roche’s investment, but the data is not the only thing that Flatiron brings to the table. Flatiron has over 800 community oncology practices in its network, and all of them are connected through Flatiron’s data infrastructure.
	5.4 Traitements - Economie
FDA Head Vows To Tackle High Drug Prices And Drugmakers ‘Gaming The System’ [KHN] “Where we see things that we can address, we’re going to take action,” Gottlieb said, adding that he is most bothered when brand-name companies use tactics to block makers of generics and biosimilars from developing drugs. He deflected questions about whether the FDA approves drugs of questionable value that carry exorbitant prices.
	5.5 ASCO
Symposium Highlights New Research on the Needs and Care of Cancer Survivors [ASCO] These select abstracts discuss new insights for the care of patients after cancer treatment, including issues of cost, patient engagement, exercise, late effects of cancer, and insomnia.
	6. Lutte contre les cancers
Retooling NCI MERIT Awards to Support Budding Cancer Researchers [NCI] We are retooling an existing grant mechanism, called the Method to Extend Research in Time (MERIT) R37 Award, using it strictly to help early-stage investigators by extending the length of time they can receive funding under their first independent NIH grant.
	6.11 Patients
Cancer, Clare and me: actor Greg Wise on the death of his sister [The Guardian] “There are 7m carers in the UK and generally with little help and almost no support from government. If they all went: ‘We can’t do this any more,’ and made the state responsible, the NHS would be bankrupt overnight.”
Living With Cancer: A Cancer Researcher Takes Cancer Personally [NY Times] A diagnosis of multiple myeloma, cancer of the plasma cells, motivated Dr. C. Anthony Blau of the University of Washington to come up with an innovative approach to his disease. He combined his research in hematology, his physician wife’s clinical expertise and crowdsourcing to develop an individualized treatment plan.
	6.6 Publications
Making Science Transparent By Default; Introducing the TOP Statement [OSF] We propose that every scientific publication incorporates a statement that discloses the availability of those research products and materials that underlie its onclusions. The particular requirements are described in the Transparency and Openness Promotion (TOP) Guidelines.
	6.7 DMP, Big Data & applis
Your private medical data is for sale – and it's driving a business worth billions [The Guardian] Although information is anonymized, data miners and brokers can build up detailed dossiers on individual patients by cross-referencing with other sources.
	6.7.2 Applis
Digital cancer patient platform offers info and support [Israel21c] Claiming to be the world’s largest digital cancer patient platform despite its staff of fewer than 50, Belong has partnerships with the American Cancer Society and Colorectal Cancer Canada (CCC), providing closed forums for members of these organizations.